Overview

Defend Against Infections with Precision Pharmacogenomics

Optimize antimicrobial therapies, reduce resistance, and streamline patient outcomes across your health system.

Overview

Infectious diseases require agile and targeted treatments to combat bacterial, viral, fungal, and parasitic pathogens—especially given rising drug resistance. PGxAI's Infectious Diseases module (PGxAegis™) integrates advanced pharmacogenomics with real-world clinical data to guide optimal drug selection and dosing for conditions ranging from common bacterial infections to complex multidrug-resistant strains. By aligning each patient's genetic profile with antimicrobial regimens, PGxAegis™ helps clinicians minimize side effects, reduce hospital stays, and improve patient recovery rates.

•

100+ essential antimicrobial drugs covered, including antibiotics, antivirals, antifungals, and antimalarials.

•

60 key genetic markers analyzed for drug metabolism, resistance profiles, and infection severity.

•

AI-driven insights updated in real time to adapt to evolving pathogens and patient-specific factors.

Key Highlights

Serving every stakeholder in healthcare

Schedule a Demo Contact Us

Broad-Spectrum Coverage

From beta-lactams to antiviral therapies like Oseltamivir, PGxAegis™ provides actionable insights across the infectious disease spectrum.

Resistance Mitigation

Genetic data helps identify potential drug resistance, guiding clinicians toward more effective, targeted therapies and prudent antibiotic stewardship.

Rapid Response

Real-time AI alerts ensure clinicians can adjust treatments quickly, reducing the risk of complications and improving outcomes.

Reimbursable Solutions

Built around recognized CPT codes, facilitating cost-effective and clinically validated infectious disease management.

Clinical Impact

Maximize Clinical Impact with PGxAI

Schedule a Demo Contact Us

Precision-Guided Therapy Optimization

PGxAI mines genotype, phenotype, and comorbidity data in real time to recommend the optimal drug–dose pair at the first prescription. By accounting for actionable allelic variants and metabolic phenotypes, it minimizes trial-and-error titration and sharply reduces severe drug–gene and drug–drug interactions.

Superior Patient Outcomes & Experience

Genomically informed prescribing lowers adverse-event rates, accelerates therapeutic response, optimizes co-administered medications and boosts adherence. Patients spend less time managing side effects and more time benefiting from treatment, enhancing both clinical endpoints and satisfaction metrics across specialties.

Demonstrable Value-Based Performance

Fewer complications, shorter lengths of stay, and reduced readmissions translate into measurable gains on CMS and private-payer quality dashboards. Institutions leveraging PGxAI can document higher quality scores and capture value-based reimbursement upside while lowering total cost of care.

Seamless Team Integration & Scalability

The platform embeds directly into leading EHRs and e-prescribing systems, delivering concise, guideline-aligned reports that support rapid decision-making for multidisciplinary teams. Standardized APIs and CDS hooks allow effortless expansion from pilot units to enterprise-wide deployment without workflow disruption.

Drug Categories

PGxAI supports a broad range of infectious disease therapies

Schedule a Demo Contact Us

Antibiotics:

Penicillins, Cephalosporins, Fluoroquinolones, Macrolides

Antivirals:

Oseltamivir, Acyclovir, Abacavir, Ribavirin

Antifungals:

Fluconazole, Voriconazole, Posaconazole

Antimalarials:

Chloroquine, Artemether, Primaquine

Immunomodulators:

Interferons for viral infections. Each recommendation is powered by a robust AI engine that factors in genetic variants (e.g., CYP2C19, CYP3A4), pathogen profiles, and clinical guidelines.

Case Study

Summit Infectious Disease Center

Schedule a Demo Contact Us

Challenge

Rising rates of treatment failure and antibiotic resistance in hospitalized pneumonia cases.

Results

30% reduction in treatment failures over 9 months, improved resistance management, and faster patient recovery times.

What's next

Ready to Shape the Future of Precision Medicine?

Empower your infectious disease teams with AI-driven pharmacogenomics that curb resistance, lower adverse events, and optimize patient recoveries.

Request a Demo

See how PGxAegis™ enhances infectious disease workflows.